Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer

Advanced HER2 Negative Breast Carcinoma Clinical Trial

Official title: An Open, Multi-center, Cohort Clinical Study of Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive and HER2-negative Advanced Breast Cancer

Status Recruiting

Clinical Trial Summary

This study is planned to include 40 patients with HER2-negative advanced breast cancer to receive fluzoparib combined with chidamide or fluzoparib combined with camrelizumab to observe and evaluate the efficacy and safety of fluzoparib combined with camrelizumab or chidamide in the treatment of HRD-positive HER2-negative advanced breast cancer.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Breast Neoplasms

• NCT number: NCT05085626
• Study type: Interventional
• Source: Tianjin Medical University Cancer Institute and Hospital
• Contact: Chunfang Hao
• Phone: 18622223686
• Email: haochf@163.com
• Status: Recruiting
• Phase: Phase 2
• Start date: February 8, 2021
• Completion date: December 31, 2024